Procore signs multi-year strategic collaboration agreement with AWS
Peter Radovich, President and COO of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a $2.18 billion market cap company that has delivered an impressive 64% return over the past year, recently executed a series of transactions involving the company’s common stock. On March 17, Radovich sold 7,879 shares at an average price of $44.21 per share, totaling approximately $348,364. Following this sale, Radovich holds 18,672 shares directly. According to InvestingPro analysis, the company maintains strong financial health with a robust current ratio of 3.1, indicating solid liquidity.
Earlier, on March 15, Radovich acquired 14,440 shares through the vesting of performance restricted stock units, which were converted at no cost. This transaction increased his direct holdings to 26,551 shares before the subsequent sale. The shares acquired through the vesting process were part of a scheduled vesting plan, with some shares sold to cover tax obligations. The company has shown remarkable revenue growth of 81% in the last twelve months. For deeper insights into MIRM’s valuation and 7 additional key ProTips, check out the comprehensive research available on InvestingPro.
In other recent news, Mirum Pharmaceuticals reported fourth-quarter earnings that fell short of analyst expectations, with an adjusted loss of $1.85 per share compared to the forecasted $0.30 loss per share. Despite this, the company’s revenue exceeded expectations, reaching $99.41 million against a consensus estimate of $95.4 million, marking a 55.6% year-over-year increase. For the full year 2024, Mirum’s total net product sales rose to $336.4 million from $178.9 million in 2023, with LIVMARLI contributing $213.3 million. The company has projected 2025 global net product sales to be between $420 million and $435 million and expects to achieve positive cash flow. H.C. Wainwright has raised its price target for Mirum to $72, maintaining a Buy rating, citing the company’s progress towards its 2025 sales guidance. Mirum is also advancing its clinical programs, including the Phase 3 EXPAND study of LIVMARLI and the Phase 2 VISTAS study of volixibat, with significant milestones expected in 2025 and 2026. Additionally, Mirum has received FDA approval to market its bile acid products for cerebrotendinous xanthomatosis, which is anticipated to drive modest growth. These developments highlight Mirum’s ongoing efforts to expand its product reach and achieve financial growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.